ArticleRedox biology2026
Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper oxide nanoparticles (CuONPs), widely used across various industries, pose inhalation risks to industrial workers and consumers through respiratory exposure. Although exposure to CuONPs has been implicated in the initiation and progression of respiratory disorders, the molecular mechanisms underlying these effects remain poorly defined. In this study, we investigated the role of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway in CuONP-induced respiratory toxicity and asthma exacerbation. Exposure to CuONPs resulted in pronounced inflammatory cell infiltration, elevated cytokine production, and excessive mucus secretion, accompanied by disrupted redox balance, as evidenced by increased malondialdehyde (MDA) levels and decreased glutathione (GSH) concentrations. These changes were associated with upregulation of Nrf2 and its downstream antioxidant enzymes, including heme oxygenase-1 (HO-1) and glutamate-cysteine ligase modifier subunit (GCLM). Although this antioxidant response is consistent with an expected oxidative stress-adaptive pathway, it was not sufficient to prevent CuONP-associated inflammatory and redox disturbances. Consistently, in NCI-H292 cells, CuONP treatment increased the expression of Nrf2, HO-1, and GCLM, whereas siRNA-mediated Nrf2 knockdown abrogated these inductions. In an ovalbumin (OVA)-induced asthma model, CuONP exposure further intensified airway inflammation and oxidative stress, despite elevated Nrf2 expression. However, adeno-associated virus (AAV)-mediated Nrf2 overexpression significantly attenuated CuONP-induced airway inflammatory responses and redox imbalance in asthmatic mice. Taken together, our results indicate that endogenous Nrf2 response is insufficient to counteract CuONP-driven asthma exacerbation, whereas pharmacological or genetic augmentation of Nrf2 signaling may constitute a viable strategy to alleviate nanoparticle-induced respiratory injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.